Could a simple shot replace IV drips for this cancer drug?
NCT ID NCT07391670
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial is testing whether giving durvalumab as a shot under the skin works as well as the standard IV infusion. About 40 adults with various solid tumours will receive the injection, and researchers will measure drug levels in the blood and watch for side effects. If successful, it could make treatment faster and more convenient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (an immunotherapy drug) given as a shot under the skin
What this could lead to
If it works, this could offer a faster, more convenient way to give durvalumab without needing an IV line.
What could go wrong
This is a very early phase 1 trial with only 40 people, so it is not yet clear if the shot works as well as the IV version. Side effects from the injection or the drug itself are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGFitzroy, 3065, Australia
-
Research Site
NOT_YET_RECRUITINGSt Albans, 3021, Australia
-
Research Site
NOT_YET_RECRUITINGWoolloongabba, 4102, Australia
-
Research Site
RECRUITINGBatumi, 6010, Georgia
-
Research Site
RECRUITINGTbilisi, 0112, Georgia
-
Research Site
RECRUITINGTbilisi, 0114, Georgia
-
Research Site
NOT_YET_RECRUITINGBrzozów, 36-200, Poland
-
Research Site
NOT_YET_RECRUITINGKoszalin, 75-581, Poland
-
Research Site
NOT_YET_RECRUITINGLublin, 20-090, Poland
-
Research Site
NOT_YET_RECRUITINGOlsztyn, 10-357, Poland
-
Research Site
RECRUITINGPrzemyśl, 37-700, Poland
-
Research Site
RECRUITINGSeongnam-si, 13620, South Korea
-
Research Site
RECRUITINGSeoul, 03722, South Korea
-
Research Site
RECRUITINGSeoul, 06351, South Korea
-
Research Site
RECRUITINGSeoul, 5505, South Korea
-
Research Site
NOT_YET_RECRUITINGTainan, 73657, Taiwan
-
Research Site
RECRUITINGTaipei, 110, Taiwan
-
Research Site
NOT_YET_RECRUITINGTaipei, 112, Taiwan
-
Research Site
NOT_YET_RECRUITINGTaoyuan, 333, Taiwan